Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec 1;110(12):3094-3098.
doi: 10.3324/haematol.2025.287408. Epub 2025 Jun 26.

Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries

Guillaume Moulis  1 , Frederick Chen  2 , Giuseppe Carli  3 , Waleed Ghanima  4 , Karolin Trautmann-Grill  5 , Thomas Stauch  6 , Alexandra Schifferli  7 , Haroon Miah  2 , Manuela Rueter  8 , Lisanna Ghiotto  9 , Riccardo Tomasello  10 , Annabell Georgi  5 , Vickie McDonald  11 , Francesco Zaja  12 , Heidi Hassel Pettersen  10 , Thomas Kühne  13 , Maria Luisa Lozano  14 , Tomás José González-López  15 , Drew Provan  16 , Marc Michel  17 , Nichola Cooper  18 , Francesco Rodeghiero  19
Affiliations

Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries

Guillaume Moulis et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Proportions of patients initiating each major maintenance immune thrombocytopenia treatment during 2010-2016 versus 2017-2022. All treatment lines are combined, over the total number of patients exposed to any immune thrombocytopenia (ITP) maintenance treatment during these periods. AZA: azathioprine; DAN: danazol; DAP: dapsone; ELT: eltrombopag; HCQ: hydroxychloroquine; MMF: mycophenolate mofetil; ROM: romiplostim; RTX: rituximab; SPL: splenectomy.
Figure 2.
Figure 2.
Proportion of first maintenance treatment in patients with primary immune thrombocytopenia over the total number of patients treated with maintenance therapy in each registry. The ITP-PARC registry (Switzerland and Serbia) was excluded due to insufficient number of selected patients (N=9). AVA: avatrombopag; AZA: azathioprine; CIC: cyclosporin; CYC: cyclophosphamide; DAN: danazol; DAP: dapsone; ELT: eltrombopag; FOS: fostamatinib; HCQ: hydroxychloroquine; MMF: mycophenolate mofetil; ROM: romiplostim; RTX: rituximab; SPL: splenectomy.
See this image and copyright information in PMC

References

    1. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817. - PMC - PubMed
    1. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866. - PMC - PubMed
    1. Moulis G, Cooper N, Ghanima W, et al. Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (ERCI) network. Br J Haematol. 2022;197(5):633-638. - PubMed
    1. Doobaree IU, Newland A, McDonald V, et al. Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry. Eur J Haematol. 2019;102(5):416-423. - PMC - PubMed
    1. Moulis G, Michel M, Bonnotte B. CARMEN-France investigators group. The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France. Rev Med Interne. 2024;45(9)543-548. - PubMed

LinkOut - more resources